Amlodipine

Generic Name
Amlodipine
Brand Names
Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
Drug Type
Small Molecule
Chemical Formula
C20H25ClN2O5
CAS Number
88150-42-9
Unique Ingredient Identifier
1J444QC288
Background

Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...

Indication

Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :

• Hypertension

• Coronary artery disease

• Chronic stable angina

• Vasospastic angina (Prinzmetal’s or Variant angina)
...

Associated Conditions
Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
Associated Therapies
-

Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

First Posted Date
2007-09-11
Last Posted Date
2009-11-11
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
185
Registration Number
NCT00527514

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

First Posted Date
2007-08-31
Last Posted Date
2012-04-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
229
Registration Number
NCT00523549
Locations
🇺🇸

Novartis Investigative Sites, USA, New Jersey, United States

Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension

First Posted Date
2007-08-31
Last Posted Date
2020-08-04
Lead Sponsor
Novartis
Target Recruit Count
257
Registration Number
NCT00523744
Locations

30 sites in Germany

🇩🇪

Novartis Investigative Site, , Germany, Schwerin, Germany

Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension

First Posted Date
2007-07-10
Last Posted Date
2014-09-10
Lead Sponsor
Novartis
Target Recruit Count
46
Registration Number
NCT00498433
Locations
🇩🇪

Novartis Investigative Site, Hannover, Germany

Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy

First Posted Date
2007-03-13
Last Posted Date
2011-05-11
Lead Sponsor
Novartis
Target Recruit Count
90
Registration Number
NCT00446563
Locations
🇩🇪

25 centers in Germany, Ludwigshafen, Germany

Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient

Phase 3
Completed
Conditions
Interventions
First Posted Date
2007-03-06
Last Posted Date
2009-10-28
Lead Sponsor
Pfizer
Target Recruit Count
134
Registration Number
NCT00443456
Locations
🇯🇵

Pfizer Investigational Site, Fukuoka, Japan

Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension

Phase 4
Completed
Conditions
First Posted Date
2007-01-24
Last Posted Date
2011-06-08
Lead Sponsor
Novartis
Target Recruit Count
480
Registration Number
NCT00425997
Locations
🇺🇸

Sites in USA, East Hanover, New Jersey, United States

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

First Posted Date
2006-12-29
Last Posted Date
2011-09-26
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
48
Registration Number
NCT00417170
Locations
🇺🇸

Novartis Investigative Site, Santa Monica, California, United States

A Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-12-25
Last Posted Date
2021-02-11
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
305
Registration Number
NCT00415623
Locations
🇯🇵

Pfizer Investigational Site, Fukuoka, Japan

© Copyright 2024. All Rights Reserved by MedPath